MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/oncolo/oyad056

Медицинская библиотека · The oncologist · 2023

The Impact of HIV Infection on Neoadjuvant and Adjuvant Chemotherapy Relative Dose Intensity in South African Patients with Breast Cancer.

O'Neil Daniel S, Ayeni Oluwatosin A, Farrow Hayley A, Chen Wenlong Carl, Demetriou Georgia, Buccimazza Ines, Čačala Sharon, Stopforth Laura W, Joffe Maureen, Antoni Michael H, Lopes Gilberto, Pumpalova Yoanna S, Mapanga Witness, Jacobson Judith S, Crew Katherine D, Neugut Alfred I, Ruff Paul, Cubasch Herbert

СтатьяПоддержка NIH: внешняя программаПеревод в очереди

Аннотация

INTRODUCTION

In the South African Breast Cancer and HIV Outcomes (SABCHO) study, we previously found that breast cancer patients living with HIV and treated with neoadjuvant chemotherapy achieve lower rates of complete pathologic response than patients without HIV. We now assess the impact of comorbid HIV on receipt of timely and complete neoadjuvant and adjuvant chemotherapy.

MATERIALS AND

METHODS

Since June 2015, the SABCHO study has collected data on women diagnosed with breast cancer at 6 South African hospitals. We selected a sample of participants with stages I-III cancer who received ≥2 doses of neoadjuvant or adjuvant chemotherapy. Data on chemotherapies prescribed and received, filgrastim receipt, and laboratory values measured during treatment were captured from patients' medical records. We calculated the mean relative dose intensity (RDI) for all prescribed chemotherapies. We tested for association between full regimen RDI and HIV status, using linear regression to control for demographic and clinical covariates, and for association of HIV with laboratory abnormalities.

RESULTS

The 166 participants living with HIV and 159 without HIV did not differ in median chemotherapy RDI: 0.89 (interquartile range (IQR) 0.77-0.95) among those living with HIV and 0.87 (IQR 0.77-0.94) among women without HIV. Patients living with HIV experienced more grade 3+ anemia and leukopenia than those without HIV (anemia: 10.8% vs. 1.9%, P = .001; leukopenia: 8.4% vs. 1.9%, P = .008) and were more likely to receive filgrastim (24.7% vs. 10.7%, P = .001).

CONCLUSIONS

HIV status did not impact neoadjuvant or adjuvant chemotherapy RDI, although patients with breast cancer living with HIV experienced more myelotoxicity during treatment.

Для цитирования: O'Neil Daniel S, Ayeni Oluwatosin A, Farrow Hayley A, Chen Wenlong Carl, Demetriou Georgia, Buccimazza Ines, Čačala Sharon, Stopforth Laura W, Joffe Maureen, Antoni Michael H, Lopes Gilberto, Pumpalova Yoanna S, Mapanga Witness, Jacobson Judith S, Crew Katherine D, Neugut Alfred I, Ruff Paul, Cubasch Herbert. The Impact of HIV Infection on Neoadjuvant and Adjuvant Chemotherapy Relative Dose Intensity in South African Patients with Breast Cancer.. The oncologist. 2023. DOI: 10.1093/oncolo/oyad056.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.